Tag: Leuprorelin

19. October 2021

AMW signs License and Supply Agreement for Commercialization of its Goserelin and Leuprorelin implants in Israel

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announced that it has entered into license and supply agreements (LSA) with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in the country of Israel.

2. November 2020

Expansion of the partnership between AMW and Zentiva for Western Europe

Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer received its first marketing authorisation in Germany in 2018 and gained market share quickly.